Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Cash flows from operating activities:    
Net income $ 11,558 $ 7,390
Adjustments to reconcile net income to net cash provided by (used in) operating activities:    
Adjustment for income from EIR method purchased receivables (3,935) (4,562)
Stock-based compensation expense 3,588 5,546
Credit losses on purchased receivables   9,000
Gain on the acquisition of Kinnate   (19,316)
Common stock contribution to 401(k) 141 118
Amortization of intangible assets 1,199  
Depreciation 6 5
Accretion of long-term debt discount and debt issuance costs 749 508
Non-cash lease expense 31 29
Change in fair value of equity securities (5,173) (535)
Change in fair value of available-for-sale debt securities classified as cash equivalents 49  
Change in fair value of derivatives (5)  
Changes in assets and liabilities:    
Trade and other receivables, net 22 478
Prepaid expenses and other assets 1,715 (603)
Accounts payable and accrued liabilities (387) 921
Operating lease liabilities (219) (82)
Unearned revenue recognized under units-of-revenue method (671) (1,117)
Net cash provided by (used in) operating activities 8,668 (2,220)
Cash flows from investing activities:    
Net cash acquired in Kinnate acquisition   18,926
Payments of consideration under RPAs, AAAs, and CPPAs (8,000) (37,000)
Receipts under RPAs, AAAs, and CPPAs 2,039 16,741
Payment for BioInvent contract-based intangible asset (20,614)  
Purchase of property and equipment   (17)
Purchase of equity securities (99)  
Net cash used in investing activities (26,674) (1,350)
Cash flows from financing activities:    
Principal payments - debt (5,065) (3,616)
Debt issuance costs and loan fees paid in connection with long-term debt (80) (661)
Payment of preferred stock dividends (2,736) (2,736)
Repurchases of common stock (2,370) (13)
Proceeds from exercise of options and other share-based compensation 896 2,353
Taxes paid related to net share settlement of equity awards (570) (1,387)
Net cash used in financing activities (9,925) (6,060)
Net decrease in cash, cash equivalents, and restricted cash (27,931) (9,630)
Cash, cash equivalents, and restricted cash as of the beginning of the period 106,416 159,550
Cash, cash equivalents, and restricted cash as of the end of the period 78,485 149,920
Supplemental cash flow Information:    
Cash paid for interest 6,078 3,780
Cash paid for taxes 277  
Non-cash investing and financing activities:    
Estimated fair value of the Exarafenib milestone asset   2,922
Estimated fair value of the Exarafenib milestone contingent consideration   2,922
Right-of-use assets obtained in exchange for operating lease liabilities in Kinnate acquisition   824
Relative fair value basis reduction of rights-of-use assets in Kinnate acquisition   (824)
Accrual of contingent consideration under the Affitech CPPA   3,000
Preferred stock dividend accrual 1,368 $ 1,368
Excise tax accrual due to stock repurchases 24  
Transaction costs in connection with BioInvent IP acquisition included in accounts payable $ 111